Gamida Cell Past Earnings Performance
Past criteria checks 0/6
Gamida Cell's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 102.5% per year.
Key information
-12.1%
Earnings growth rate
25.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 102.5% |
| Return on equity | n/a |
| Net Margin | -2,318.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Gamida Cell shares slide after stock offering
Sep 27Gamida appoints Emergent’s former head of vaccines as new CEO
Sep 19Gamida Cell Q2 2022 Earnings Preview
Aug 12Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel
Aug 01Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?
Feb 23
Gamida Cell: Recapping A Tough Year
Nov 02Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?
Nov 02Revenue & Expenses Breakdown
How Gamida Cell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -62 | 53 | 18 |
| 31 Dec 23 | 2 | -63 | 45 | 24 |
| 30 Sep 23 | 1 | -77 | 44 | 33 |
| 30 Jun 23 | 0 | -93 | 38 | 38 |
| 31 Mar 23 | 0 | -80 | 35 | 40 |
| 31 Dec 22 | 0 | -79 | 32 | 43 |
| 30 Sep 22 | 0 | -80 | 32 | 45 |
| 30 Jun 22 | 0 | -86 | 36 | 47 |
| 31 Mar 22 | 0 | -91 | 37 | 50 |
| 31 Dec 21 | 0 | -90 | 37 | 50 |
| 30 Sep 21 | 0 | -87 | 37 | 48 |
| 30 Jun 21 | 0 | -79 | 31 | 46 |
| 31 Mar 21 | 0 | -70 | 25 | 42 |
| 31 Dec 20 | 0 | -62 | 22 | 39 |
| 30 Sep 20 | 0 | -55 | 18 | 37 |
| 30 Jun 20 | 0 | -50 | 17 | 34 |
| 31 Mar 20 | 0 | -29 | 17 | 32 |
| 31 Dec 19 | 0 | -34 | 17 | 31 |
| 30 Sep 19 | 0 | -42 | 16 | 27 |
| 30 Jun 19 | 0 | -42 | 14 | 25 |
| 31 Mar 19 | 0 | -61 | 14 | 24 |
| 31 Dec 18 | 0 | -53 | 12 | 22 |
| 30 Sep 18 | 0 | -36 | 9 | 21 |
| 30 Jun 18 | 0 | -30 | 7 | 20 |
| 31 Mar 18 | 0 | -22 | 5 | 16 |
| 31 Dec 17 | 0 | -19 | 4 | 15 |
Quality Earnings: GMDA.Q is currently unprofitable.
Growing Profit Margin: GMDA.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GMDA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare GMDA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GMDA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GMDA.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/26 18:30 |
| End of Day Share Price | 2024/05/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gamida Cell Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Vernon Bernardino | H.C. Wainwright & Co. |